Results 121 to 130 of about 48,841 (237)

A case report of immune checkpoint inhibitor‐related myositis and cholangitis induced by pembrolizumab

open access: yesClinical Case Reports
Key Clinical Message Rare but severe, immune‐related adverse events such as myositis and sclerosing cholangitis can occur with immune checkpoint inhibitors in lung cancer treatment.
Takafumi Yamano   +3 more
doaj   +1 more source

Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis.

open access: yes, 1986
The aetiology of primary sclerosing cholangitis is unknown, but it is closely associated with ulcerative colitis. Serum anticolon antibodies, crossreacting with portal tracts, have been reported in patients with ulcerative colitis but no studies have ...
W S Selby   +5 more
core   +1 more source

Recent Development of Endo‐hepatology

open access: yesDEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Endo‐hepatology is a rapidly evolving field encompassing endoscopic diagnosis and treatment of hepatobiliary diseases, primarily using endoscopic ultrasound (EUS). Since its conceptualization in 2012, the field has expanded dramatically alongside advances in interventional EUS. A landmark 2024 review broadened the concept to include endoscopic
Akira Yamamiya   +3 more
wiley   +1 more source

Primary sclerosing cholangitis associated with severe ulcerative colitis in a young man

open access: yesAutopsy and Case Reports, 2013
Primary sclerosing cholangitis, a chronic progressive cholestatic liver disease, is the most serious hepatobiliary complication of ulcerative colitis (UC).
José Cândido Caldeira Xavier Júnior   +5 more
doaj  

Prevention and treatment of post‐endoscopic retrograde cholangiopancreatography cholangitis: Current evidence and future directions

open access: yesClinical and Translational Discovery, Volume 6, Issue 6, December 2026.
1. Prevention strategies should be stratified by preoperative cholangitis status. 2. For pre‐existing cholangitis, therapeutic antibiotics plus urgent drainage are essential; ENBD and stents show similar efficacy. 3. Early biliary drainage is the cornerstone of treatment; endoscopic drainage is preferred, with PTCD/EUS‐BD as second‐line. 4.
Hao‐Xin Chen, Jun Yao
wiley   +1 more source

Associations Between Liver Biomarkers and Clinical Outcomes in Patients With Primary Sclerosing Cholangitis: A Retrospective Real‐World Study

open access: yesLiver International Communications, Volume 7, Issue 4, December 2026.
ABSTRACT Background and Aims This retrospective observational study assessed whether liver biomarker levels and their temporal changes can predict clinical outcomes in patients with primary sclerosing cholangitis (PSC). Approach and Results Adults with any cholangitis diagnosis in the TriNetX Dataworks‐USA network during the study period (2011–2021 ...
Jun Xu   +10 more
wiley   +1 more source

Immunoglobulin G4-related sclerosing cholangitis [PDF]

open access: yes, 2018
Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibroinflammatory condition of which IgG4-related sclerosing cholangitis (IgG4-SC) is the biliary manifestation.
Pereira, SP, Webster, G, Goodchild, G
core   +1 more source

DUCK‐Net: automated deep learning segmentation of ductular reactions in murine liver injury captures multicellular niche dynamics from H&E morphology

open access: yesThe Journal of Pathology, Volume 270, Issue 4, Page 441-454, December 2026.
Abstract Ductular reactions (DRs) are dynamic and complex multicellular responses that occur as a result of various hepatic injuries. Precise identification and quantification of the extent of DRs is a cornerstone of pre‐clinical modelling of liver disease, with links to inflammation, fibrosis, regeneration, and disease severity.
Nathalie Feeley   +15 more
wiley   +1 more source

Genetic Spectrum of Cholestasis in Tunisia and Diagnostic Yield of Next‐Generation Sequencing: Case Series of 70 Patients

open access: yesClinical Genetics, Volume 110, Issue 6, Page 716-723, December 2026.
Genetic hepatic cholestasis: NGS diagnostic yield. Over a 10‐year period, NGS (gene panel/WES) established a genetic diagnosis in 70% of 66 families with hepatic cholestasis, with a molecular yield of 62%. ABCB11 was the most mutated gene, and PFIC Type 2 was the leading diagnosis, underscoring the critical role of NGS in guiding genetic counseling and
Amal Abdmouleh   +12 more
wiley   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11394-11406, December 2026.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy